Skip to main content

Cardiovascular outcomes


08-09-2017 | Sodium-glucose co-transporter-2 inhibitors | News

Support for cardioprotective effects of SGLT2 inhibitors

Patients with type 2 diabetes receiving treatment with sodium-glucose co-transporter-2 inhibitors have a lower risk for adverse cardiovascular outcomes than those using other glucose-lowering drugs, results from the CVD-REAL Nordic study suggest.

08-01-2017 | Canagliflozin | News

Cardiac biomarker data support canagliflozin cardioprotective effect

Treatment with canagliflozin has positive effects on biomarkers of cardiovascular disease risk in older patients with type 2 diabetes, research shows.

07-20-2017 | Cardiovascular outcomes | News

Machine learning hints at complex treatment effects in Look AHEAD

A machine-learning analysis suggests the existence of heterogeneous treatment effects in the Look AHEAD trial, which could account for the overall neutral effect of the study intervention on cardiovascular outcomes.

Read more


01-13-2017 | Cardiovascular outcomes | Editorial | Article

Clinical implications of cardiovascular outcomes trials in type 2 diabetes

What do the results of CVOTs mean for practicing clinicians? Editorial board member Carol Hatch Wysham reviews the latest evidence and guidelines for reducing CV risk in patients with type 2 diabetes.

ORIGIN trial in patients with type 2 diabetes

This downloadable slide set summarizes the design and results of the ORIGIN study, which investigated the effect of titrated basal insulin glargine versus standard care and n-3 fatty acids versus placebo on cardiovascular (CV) outcomes in patients with (or at risk for) type 2 diabetes and other CV risk factors.

View and download slides

Journal articles and book chapters

02-02-2017 | Cardiovascular outcomes | Review | Article

Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes

Many of the currently available oral anti-diabetic agents have clinically relevant cardiovascular effects. This expert review concludes that optimal approach to the reduction of cardiovascular risk in diabetic patients should focus on aggressive management of the standard cardiovascular risk factors rather than purely on intensive glycemic control.

Xu J & Rajaratnam R. Cardiovasc Diabetol 2017;16:18. doi:10.1186/s12933-017-0499-5

01-26-2017 | Hypertension | Review | Article

Blood pressure control in type 2 diabetic patients

What is the best method for controlling hypertension in patients with diabetes, and what should be the goal? This review takes a look at the evidence and guidelines supporting different BP targets, and provides an overview of the available treatment options, including the new classes of anti-diabetic drugs.

Grossman A & Grossman E. Cardiovasc Diabetol 2017;16:3. doi:10.1186/s12933-016-0485-3

01-20-2017 | Hypertension | Review | Article

Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME

What is the optimal BP target in diabetes mellitus? A review of the implications of the ACCORD-BP, SPRINT and EMPA-REG OUTCOME trials and previous studies.

Nat Rev Endocrinol 2017;13:365–374. doi:10.1038/nrendo.2016.209

Pantelis Sarafidis, Antonios Lazaridis, Gema Ruiz-Hurtado, Luis Ruilope
image credits